Amarantus Bioscience Holdings, Inc. – "Marching Towards a Revolutionary Therapy for Blindness and Diabetes in Wolfram Syndrome"

Publishing & Media

Share Tweet

Amarantus Bioscience Holdings, Inc. – "Marching Towards a Revolutionary Therapy for Blindness and Diabetes in Wolfram Syndrome"

New York, NY / June 24, 2014 / Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS) today published a guest blog post on The Chairman’s Blog, written by Dr. Fumihiko Urano, a researcher at the Washington University School of Medicine. is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

In his guest blog post, Dr. Urano discusses the recently announced collaboration between the Washington University School of Medicine in St. Louis and Amarantus, in which his team will test the efficacy of MANF for the treatment of Wolfram’s syndrome and potentially, Type-1 diabetes. Commenting on the collaboration, Dr. Urano wrote, "Now that I have finally been able to forge a pact with Amarantus on an area where we share mutual interest...We are all hopeful that a breakthrough is on the horizon." Read the full blog post from Dr. Fumihiko Urano on (

About Amarantus

Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. The Company has licensed Eltoprazine ("Eltoprazine"), a phase 2b ready indication for Parkinson's Levodopa induced dyskinesia and Adult ADHD. The Company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test(R)") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard"). For further information please visit, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.

About is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. 

SOURCE: The Chairmans Blog